-
COVID Westward Migration Continues
Key Points: In today’s Recommendation for Industry, we take a look at the latest statistics on COVID and expectations for the next few months. Read more below. FDA advisory committee is recommending Omicron variant to be within COVID boosters. The proportion of BA.4 and BA.5 increased in the week ending June 25th, mainly due to…
-
COVID-19 & Monkeypox Updates
Key Points: In today’s Recommendation for Industry, we provide updates on COVID-19 and Monkeypox. Read more below. Pfizer’s Omicron-Targeting COVID-19 Vaccines Generate Stronger Immune Response. A modified booster shot targeting Omicron specifically increased neutralizing antibody levels 13.5 to 19.6 times higher than the current shot. A booster targeting both Omicron and the original virus increased…
-
Monkeypox: Steps Businesses Can Take to Keep Risk Low
Key Points: In today’s Recommendation for Industry, we discuss the low risk of monkeypox in the US, and what businesses can do to keep it low. Read more below. Omicron is as much as 50% less likely to lead to long COVID, study finds. The numbers of individuals that were infected with Omicron were more…
-
COVID Trends Continue, but Severity Remains Low
Key Points: In today’s Recommendation for Industry, we discuss the current data on COVID case rates and hospitalizations. Read more below. FDA committee approves Moderna COVID vaccine for kids 6 to 17. Previously only Pfizer was approved for ages 5-17 and the CDC had recommended that age range receive a single-dose booster. The CDC reports…
-
Monkeypox: What It Is and How It Spreads
Key Points: In today’s Recommendation for Industry, we discuss the recent monkeypox outbreak. Read more below. In-utero COVID exposure tied to language, motor delays by 1 year. Infants born to mothers infected with SARS-CoV-2 during pregnancy were more likely to receive a neurodevelopmental diagnosis by 1 year of age, regardless of whether they were born…